European CHMP adopts positive opinion for Gilead’s zydelig® (idelalisib) for the treatment of chronic lymphocytic leukemia and follicular lymphoma
25 July 2014 | By Gilead
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for Zydelig®...